

# 1 **A randomised controlled pilot trial of oral 11 $\beta$ -HSD1 inhibitor** 2 **AZD4017 for wound healing in adults with type 2 diabetes mellitus**

## 3 **Single Sentence Summary**

4 AZD4017 was safe; data suggested improved skin healing / integrity, and modestly reduced  
5 epidermal barrier function in patients with type 2 diabetes.

## 6 **Authors**

7 Ramzi Ajjan<sup>1</sup>, Elizabeth MA Hensor<sup>2,3</sup>, Kave Shams<sup>2,4</sup>, Francesco Del Galdo<sup>2,3</sup>, Afroze Abbas<sup>1</sup>, Janet  
8 Woods<sup>5</sup>, Rebecca J Fairclough<sup>6</sup>, Lorraine Webber<sup>7</sup>, Lindsay Pegg<sup>7</sup>, Adrian Freeman<sup>6</sup>, Ann Morgan<sup>1,3</sup>,  
9 Paul M Stewart<sup>3,8</sup>, Angela E Taylor<sup>9</sup>, Wiebke Arlt<sup>9</sup>, Abd Tahrani<sup>9</sup>, David Russell<sup>1,5</sup> and Ana Tiganeşcu<sup>1,3</sup>

## 10 **Affiliations**

11 <sup>1</sup>Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

12 <sup>2</sup>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

13 <sup>3</sup>NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK

14 <sup>4</sup>Leeds Centre for Dermatology, Chapel Allerton Hospital, Leeds, UK

15 <sup>5</sup>Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK

16 <sup>6</sup>Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge,  
17 UK

18 <sup>7</sup>Emerging portfolio development, Late Oncology, Oncology R&D, AstraZeneca, Cambridge, UK

19 <sup>8</sup>Faculty of Medicine and Health, University of Leeds, Leeds, UK

20 <sup>9</sup>Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK;  
21 Centre of Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health partners,  
22 Birmingham, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NIHS  
23 Foundation Trust, Birmingham, UK

24

25 Acronym: Glucocorticoids and Skin Healing in Diabetes (GC-SHEALD)

26 Keywords: Glucocorticoid

27 Skin

28 Wound healing

29 11 beta hydroxysteroid dehydrogenase type 1

30 Type 2 diabetes mellitus

31 Randomised controlled trial

32 Corresponding author: Ana Tiganescu

33 Leeds Institute of Cardiovascular and Metabolic Medicine

34 School of Medicine, LIGHT Building, Clarendon Way

35 University of Leeds, LS2 9JT, UK

36 0113 34 38336

37 a.tiganescu@leeds.ac.uk

38 Disclosure Summary: I certify that neither I nor my co-authors have a conflict of interest as described

39 above that is relevant to the subject matter or materials included in this Work.

## 40 Abstract

41 Chronic wounds (e.g. diabetic foot ulcers) have a major impact on quality of life, yet treatments  
42 remain limited. Glucocorticoids impair wound healing; preclinical research suggests that blocking  
43 glucocorticoid activation by the enzyme 11 $\beta$ -hydroxysteroid dehydrogenase type 1 (11 $\beta$ -HSD1)  
44 improves wound repair. This investigator-initiated double-blind, randomised, placebo-controlled  
45 parallel-group phase 2b pilot trial investigated efficacy, safety and feasibility of 11 $\beta$ -HSD1 inhibition  
46 for 35 days by oral AZD4017 (AZD) treatment in adults with type 2 diabetes (n=14) compared to  
47 placebo (PCB, n=14) in a single-centre secondary care setting. Computer-generated 1:1  
48 randomisation was pharmacy-administered. From 300 screening invitations, 36 attended, 28 were  
49 randomised. There was no proof-of-concept that AZD inhibited 24 hour skin 11 $\beta$ -HSD1 activity at day  
50 28 (primary outcome: adjusted difference AZD-PCB 90% CI (diffCI)=-3.4,5.5) but systemic 11 $\beta$ -HSD1  
51 activity (median urinary [THF+alloTHF]/THE ratio) was 87% lower with AZD at day 35 (PCB 1.00, AZD  
52 0.13, diffCI=-1.04,-0.69). Mean wound gap diameter (mm) following baseline 2mm punch biopsy was  
53 34% smaller at day 2 (PCB 1.51, AZD 0.98, diffCI=-0.95,-0.10) and 48% smaller after repeat wounding  
54 at day 30 (PCB 1.35, AZD 0.70, diffCI=-1.15,-0.16); results also suggested greater epidermal integrity  
55 but modestly impaired barrier function with AZD. AZD was well-tolerated with minimal side effects  
56 and comparable adverse events between treatments. Staff availability restricted recruitment  
57 (2.9/month); retention (27/28) and data completeness (95.3%) were excellent. These preliminary  
58 findings suggest that AZD may improve wound healing in patients with type 2 diabetes and warrant  
59 a fully-powered trial in patients with active ulcers. [Trial Registry: [www.isrctn.com/ISRCTN74621291](http://www.isrctn.com/ISRCTN74621291).  
60 Funding: MRC Confidence in Concept and NIHR Senior Investigator Award.]

## 61 Introduction

62 Chronic, non-healing wounds e.g. diabetic foot ulcers are a common worldwide health problem that  
63 have substantial medical and socioeconomic importance and represent a major unmet clinical need  
64 (1). In Europe, 1-1.5% of the population has a problem wound at any one moment in time. The  
65 average cost per episode is 6,650€ for leg ulcers and 10,000€ for foot ulcers, accounting for 2-4% of  
66 the healthcare budget and likely to escalate with an increasingly elderly and diabetic population (2).  
67 In the West Yorkshire UK region the overall prevalence of wounds is 2.8-3.6 people per 1000  
68 population (3), up to 50% of which are chronically inflamed, non-healing wounds. Costs for wound  
69 care in the UK are estimated at £2.03-3.8 million per 100,000 population (4) and diabetes currently  
70 accounts for approximately 10% of the total health resource expenditure and is projected to  
71 increase to 17% by 2035 (5).

72 The profound atrophic effects of glucocorticoids (GC) on human skin structure and function are well  
73 documented, causing decreased collagen content, increased transepidermal water loss (TEWL),  
74 dermal and epidermal thinning, telangiectasia, impaired wound healing (WH) and increased  
75 infection risk (6-13). Keratinocytes, melanocytes, fibroblasts and sebocytes play significant roles as  
76 GC targets in these processes (11, 14). These effects arise from GC excess including systemic (7, 8)  
77 and topical (10) GC therapy, Cushing's disease (6) and psychological stress (13, 15-17).

78 The expertise of our group has focused on 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD) isozymes  
79 which regulate local GC availability in many tissues largely independently of circulating levels (18). In  
80 skin, 11 $\beta$ -HSD1 generates cortisol from cortisone, is expressed in epidermal keratinocytes, hair  
81 follicles, sebaceous glands and dermal fibroblasts and is upregulated by GC in a forward-feedback  
82 manner (19, 20). Conversely, 11 $\beta$ -HSD2 converts cortisol to cortisone and, in skin, is predominantly  
83 expressed in eccrine (sweat) glands where it functions to protect the mineralocorticoid receptor  
84 from inappropriate activation by GC (as with other mineralocorticoid-responsive tissues e.g. kidney)  
85 (21). We recently demonstrated increased 11 $\beta$ -HSD1 activity during the inflammatory phase of  
86 wound healing in a mouse model (22) and faster healing in 11 $\beta$ -HSD1-null mice treated with oral  
87 corticosterone (active GC in mouse) and topical application of carbenoxolone (CBX), an 11 $\beta$ -HSD  
88 non-selective inhibitor (23). Strikingly, mice with global deletion of 11 $\beta$ -HSD1 were also protected  
89 from age-induced dermal atrophy, with improved collagen processing and accelerated wound  
90 healing (19). Others have also reported accelerated wound healing by 11 $\beta$ -HSD1 blockade in animal  
91 models of diabetes and GC excess (24, 25).

92 These findings suggest that 11 $\beta$ -HSD1 mediates the effects of circulating GC in skin and drives the  
93 cutaneous consequences of GC excess. However, the role of 11 $\beta$ -HSD1 in regulating skin function in  
94 man remains unexplored, despite evidence that 11 $\beta$ -HSD1 is upregulated by pro-inflammatory  
95 cytokines e.g. IL-1 $\beta$  and TNF (26-28) abundant in chronic wounds, and reports of increased systemic  
96 GC levels in patients with type 2 diabetes mellitus (T2DM) (29, 30). Moreover, pro-inflammatory  
97 cytokines and GC synergistically increase 11 $\beta$ -HSD1 expression (31) which may exacerbate GC  
98 availability and further impede wound healing.

99 Targeting 11 $\beta$ -HSD1 through selective inhibitors has been a focus of major pharma for the last 10  
100 years, the main target indication being metabolic syndrome to improve glucose tolerance, reduce  
101 hepatic gluconeogenesis, steatosis and visceral adipogenesis. Proof of concept was established in a

102 number of phase 2 studies but effect size prevented progression to phase 3 studies (32-35).  
103 However, the ability of systemic 11 $\beta$ -HSD1 inhibitors to target enzyme activity in skin and regulate  
104 skin function in humans is unknown.

105 Our trial objectives were to generate efficacy, safety and study feasibility data to inform a future  
106 confirmatory phase 2b trial in patients with diabetic foot ulcers. Our study variables were a  
107 combination of validated disease-related outcomes and skin-specific measures previously  
108 unexplored in T2DM that greatly improve our knowledge GC metabolism as a regulator of skin  
109 function.

## 110 **Results**

111 A Consolidated Standards of Reporting Trials (CONSORT) flow diagram is presented in Figure 1.

### 112 **Feasibility**

113 Assessment of recruitment, eligibility, consent and data completeness found conduct of a future  
114 confirmatory trial to be feasible. Further details are provided in Appendix 1.

### 115 **Participant demographics and baseline variables**

116 Participant demographics, baseline efficacy and laboratory safety variables are presented in Table 1.  
117 Full descriptive summaries of efficacy and laboratory safety variables are presented in Tables S1 and  
118 S2, respectively. The two randomised arms were well balanced for efficacy and safety variables with  
119 the possible exception of sudomotor function in the feet and platelets, which were higher and  
120 diastolic BP which was lower in the AZD4017 arm.

### 121 **Compliance**

122 Mean diary card compliance was >97.9% across both arms at all visits and >99.6% at day 35. Mean  
123 IMP compliance at each visit was >95.2% across both arms and reached >97.9% at day 35; overall  
124 IMP compliance was 84-101% (PCB) and 93-101% (AZD4017) (Table S3). Drug exposure data in  
125 plasma and skin did not indicate any discrepancies between reported compliance and actual  
126 exposure, suggesting participants had correctly adhered to the treatment regimen. Further, in the  
127 group receiving AZD4017 (n=12 with data available), there was a moderate correlation of  
128 Spearman's rho=0.54 between levels in the skin, taken from the biopsy at day 28, and in plasma  
129 samples taken at day 35 (Figure S1).

### 130 **Efficacy**

#### 131 *11 $\beta$ -HSD1 activity in skin*

132 Our primary outcome evaluated the ability of AZD4017 to inhibit 11 $\beta$ -HSD1 activity in skin. Median  
133 11 $\beta$ -HSD1 activity (% conversion per 24hr) by radioassay at day 28 was similar across treatment  
134 groups [adjusted for baseline activity, baseline glycated haemoglobin (HbA1c), age and sex: median  
135 PCB=11.8, AZD4017=12.8; difference AZD-PCB (90% CI) 1.1 (-3.4, 5.5)] (Figure 2a, Table 2), similar to  
136 unadjusted estimates (Table S4) and comparable to baseline (Table 1). Proof-of-concept was not met  
137 because median activity was higher in the AZD4017 group than placebo at day 28; all CIs included 0.  
138 This conclusion was unaffected after removal of 2 baseline samples which failed QC prior to re-  
139 imputation (Table S5). Changes from baseline (Tables S6-S7) indicated that activity went down in  
140 both PCB and AZD4017 groups, but to a greater extent in PCB.

141 A sensitivity analysis was conducted using an alternative ELISA method, which demonstrated an  
142 acceptable correlation with the radioassay method at baseline ( $\rho=0.70$ ) but not day 28 ( $\rho=0.19$ )  
143 (Figure S2, Table 3). In the primary analysis, median activity measured via ELISA was lower in the  
144 AZD4017 group, but all CIs included 0. In a sensitivity analysis which excluded an extremely high  
145 outlier in the placebo group (Table S5), the median was higher in the AZD4017 group, consistent  
146 with the radioassay method finding. Therefore, and mindful of the relatively low levels of *ex vivo*  
147  $11\beta$ -HSD1 activity over 24 hours, there was no proof-of-concept that AZD4017 was able to inhibit  
148  $11\beta$ -HSD1 activity in skin.

#### 149 *Systemic $11\beta$ -HSD1 activity*

150 In contrast to the findings in the skin, systemic  $11\beta$ -HSD1 activity, measured by urinary  
151 [THF+alloTHF]/THE ratio, differed to a substantive degree between groups at day 35. Values were  
152 lower in the AZD4017 group; adjusted median PCB=1.00, AZD4017=0.13; difference (90% CI) -0.87  
153 (1.04, -0.69) (Figure 2b, Table 2). All supplementary CI up to 95% excluded 0. This suggests median  
154 systemic  $11\beta$ -HSD1 activity may be  $\geq 69\%$  (median 87%) lower in subjects taking AZD4017. As  
155 anticipated, there was no evidence that urinary F/E ratio (a measure of systemic  $11\beta$ -HSD2 which  
156 deactivates cortisol to cortisone; unplanned analysis) was affected by AZD4017 (Figure 2c, Table 2).

#### 157 *Wound healing*

158 Separate biopsies were taken at baseline and day 28 from the outer forearm. In each case, based on  
159 maximal granulation tissue width (a marker of early wound healing), there was preliminary evidence  
160 that the mean wound gap 2 days following the biopsy differed between groups, at all levels of  
161 confidence. The 90% CI suggested that the mean gap was potentially 7% to 63% (mean 34%)  
162 narrower at day 2 and 12% to 85% (mean 48%) narrower at day 30 in the AZD4017 group, relative to  
163 placebo (Figure 3a-b, Table 2). Representative wound healing images for participants treated with  
164 placebo and ADZ4017 (Figure 3c) are presented.

165 Based on maximal clot depth (a marker of late wound healing), when re-measured 7 days post  
166 biopsy, there was no preliminary evidence of a difference between groups at either time-point (on  
167 days 7 and 35, Table 2).

#### 168 *Epidermal barrier function*

169 Resting transepidermal water loss (TEWL), the gold-standard measure of epidermal barrier function,  
170 was on average 33% higher in the AZD4017 group on day 35 (Figure 3d, Table 2), suggesting a  
171 potentially deleterious effect on epidermal barrier function. Although CIs were wide, some excluded  
172 0; at 85% confidence the results suggested between +1% and +75% higher TEWL in the AZD4017  
173 group, but the 90% CI was -3% to +82%.

174 Sensitivity analysis re-estimated the 90% CI to be +3% to +88% (Table S5).

#### 175 *Epidermal integrity*

176 The number of tapes required to achieve a barrier disruption TEWL of 40-50 g/h/m<sup>2</sup> on day 28 was  
177 observed to be higher in the AZD4017 group (at all levels of confidence). The 90% CI indicated  
178 preliminary evidence of a difference of between +7% and +91% (mean +43%) relative to placebo  
179 (Figure 3e, Table 2). This was equivalent to an additional 16.8 tapes required to induce a comparable  
180 degree of barrier disruption in the AZD4017 group.

### 181 *Epidermal barrier recovery*

182 In the first set of post-disruption recovery measurements, collected between baseline and day 7,  
183 there was no proof-of-concept for a difference in TEWL; all CIs straddled 1 (Table 2).

184 In the second set, collected between day 28 and day 35, there was some preliminary evidence of  
185 potential differences in 3hr and 48hr recovery, although CIs were wide. For 3hr post-disruption, the  
186 90% CI included 0 (-1% to +79%) but with 85% confidence, this may be between 3% and 72% higher  
187 (mean +33%) in the AZD4017 group following 28 days of treatment (Figure 3f, Table 2). Similarly, the  
188 primary 90% CI included 0 for 48hr post-disruption TEWL (-6% to 67%), but at 80% confidence there  
189 was preliminary evidence of higher TEWL in the AZD4017 group by +1% to 56% (mean +26%)  
190 relative to placebo (Figure 3g, Table 2). By 168hr post-disruption, although median TEWL was still  
191 higher in the AZD4017 group, all CI included 0 (no difference) (Table 2).

192 Sensitivity analyses did not differ from the main conclusions (table S5, S8).

### 193 *Epidermal thickness*

194 Although median epidermal thickness was greater in the AZD4017 group, consistent with proof-of-  
195 concept, all CIs included 0 (no difference) (Table 2). The 90% CI indicated that median skin thickness  
196 could be between 8% thinner to 26% thicker in the AZD4017 group relative to placebo.

### 197 *Skin hydration*

198 Although the medians suggested better hydration in the AZD4017 group, consistent with proof-of-  
199 concept, the 90% CI indicated median hydration could be anywhere between 7% lower and 37%  
200 higher in those receiving AZD4017; all CIs included 0 (Table 2).

### 201 *Sudomotor function*

202 Across all sites, sudomotor function was equivocal as an effect in a particular direction; all CI  
203 included 0 (Table 2). This was also true when the results were averaged across hands and feet  
204 separately. The 75% and 80% CIs excluded 0 in the left hand (but not the right) with 80% CI  
205 indicating between 2% and 36% greater function.

206 Sensitivity analyses indicated at 75% CI the possibility of between 1% and 13% lower sudomotor  
207 function in feet and in those taking AZD4017 relative to placebo.

### 208 **Correlations between compliance and efficacy outcomes**

209 Several outcome measures displayed preliminary evidence of an association with compliance  
210 (absolute  $\rho \geq 0.3$ ) including negative associations with 11 $\beta$ -HSD1 activity by ELISA and  
211 [THF+alloTHF]/THE ratios and positive associations with TEWL and skin hydration (table S11).  
212 However, given the narrow range of compliance variability (and overall high compliance), these  
213 putative associations should be interpreted with caution.

### 214 **Additional sensitivity analyses of primary and secondary variables**

215 Sensitivity analyses using available case (Table S9) and last observation carried forward (Table S10)  
216 as alternative methods of handling missing data did not yield results that differed substantially from  
217 the results of the main analyses, unless already highlighted above.

## 218 **Safety**

### 219 *Biopsy and ECG*

220 Biopsy sites did not raise any clinical concerns and all were found to pass a physical inspection. No  
221 incidents of infection were observed. Participants did not report any pain or discomfort from the  
222 biopsies, which all healed relatively well.

223 No clinically meaningful ECG anomalies were found in any patients remaining in the trial at day 42  
224 (placebo n=13; AZD4017 n=14).

### 225 *Longitudinal laboratory safety data*

226 The 90% CI for the (baseline value, age, sex and baseline HbA1c) adjusted difference between  
227 treatment groups indicated there was preliminary evidence that in the AZD4017 group relative to  
228 placebo (Table 3): dehydroepiandrosterone sulphate (DHEAS) was higher at days 7, 28, 35 & 42  
229 (Figure 4a), cholesterol was lower at days 7, 28 and 35 (Figure 4b), high density lipoprotein (HDL)  
230 was lower at day 35 (Figure 4c) and systolic blood pressure (BP) was lower at day 28 (Figure 4d).

231 Mean corpuscular Hb (Figure 4e) and potassium (Figure 4f) were lower at day 7, sodium was lower  
232 at day 42 (Figure 4g), creatinine was higher at day 7 (Figure 4h) and free thyroxine was higher at day  
233 42 (Figure 4i). Most of these apparent differences were small in magnitude. For all except sodium,  
234 potassium and free thyroxine, the adjusted difference at day 42, 7 days after the end of treatment,  
235 was smaller than at day 35.

236 The remaining continuous safety variables did not show any preliminary differences between  
237 AZD4017 and placebo in this study, although this may have been due to the small sample size and  
238 relatively short treatment duration (Table 3). Unadjusted estimates (Table S12) were similar,  
239 although platelets were higher in AZD at each visit, values were already higher at baseline in this  
240 group. Unadjusted and adjusted changes from baseline are presented for all laboratory safety  
241 variables in Tables S13 and S14 respectively.

242 Although there were several values in each treatment group that were above or below accepted  
243 clinical normal limits (Table S15), there were relatively few laboratory findings that were sufficient  
244 cause for concern to warrant further investigation or intervention by the study team, and none  
245 resulted in withdrawal from IMP.

### 246 *Adverse events*

247 There were a total of 37 adverse events (AE) (placebo n=13; AZD4017 n=24); counting recurring  
248 instances of the same AE within a patient just once, there were 29 unique AE (placebo n=13;  
249 AZD4017 n=16) (Table 4). The majority of AE were gastrointestinal, nervous system or respiratory,  
250 and the majority were of mild severity (n=26), with only 3 of moderate severity and none of greater  
251 severity. None of the 29 unique AE were considered probably or definitely study drug related, most  
252 were deemed possibly related (n=20) or unlikely to be relate (n=8). AE were broadly balanced across  
253 the treatment arms, although all three of the moderately severe events occurred in the AZD4017  
254 group.



255 **Future study power estimation**

256 Based on the power calculations from the current trial (table S16), we anticipate that n=100-150 per  
257 arm should suffice to detect a difference of 20% or more relative to placebo for all outcome  
258 measures.

259 **Discussion**

260 Our double-blind, randomised, placebo-controlled, parallel clinical trial provides preliminary  
261 evidence that wounds were 12-85% (mean 48%) smaller and skin integrity was 7-91% (mean 43%)  
262 stronger in patients with type 2 diabetes mellitus following 11 $\beta$ -HSD1 inhibition. This represents a  
263 major advance in the development of 11 $\beta$ -HSD1 inhibitors as a novel therapy for diabetic ulcers.

264 Studies had previously demonstrated effective 11 $\beta$ -HSD1 inhibition in mouse skin (19, 23), but this  
265 had not been explored in humans. Our primary outcome measure failed to evidence 11 $\beta$ -HSD1  
266 inhibition in skin. However, preliminary proof-of-concept was demonstrated through a reduction in  
267 [THF+alloTHF]/THE ratios (the gold-standard measure of systemic 11 $\beta$ -HSD1 activity) and elevated  
268 DHEAS consistent with other selective 11 $\beta$ -HSD1 inhibitor trials, including AZD4017 (34, 36-39). As  
269 anticipated, 11 $\beta$ -HSD2 activity was unaffected (40, 41). The lack of peripheral inhibition was not due  
270 to a lack of exposure *in situ* as skin biopsy AZD4017 correlated with plasma levels, albeit at lower  
271 concentrations. However, a loss of efficacy *ex vivo* (lower target affinity when removed from much  
272 higher *in situ* circulating AZD4017 levels) or insufficient assay sensitivity (mean baseline 11 $\beta$ -HSD1  
273 activity was relatively low) may explain this finding.

274 Our secondary outcomes offer a series of novel insights into the effects of 11 $\beta$ -HSD1 inhibition on  
275 skin function. OCT is a validated method for non-invasive assessment of wound healing (42) and our  
276 study is the first application of this method in a randomised controlled trial. Our preliminary finding  
277 of improved wound healing at day 2 post-biopsy after less than two days' AZD4017 treatment is very  
278 promising. More so, given that overall healing in this cohort was relatively normal and the diabetes  
279 relatively well-managed. Evidence indicative of improved healing by AZD4017 was obtained after  
280 just two days of treatment and the preliminary estimates of effect size were greater after 30 days  
281 treatment. The fact that all CI included considerable improvements relative to placebo, and this was  
282 finding was repeatable in the two separate biopsies, provides good justification for progressing to a  
283 larger trial. This novel human data is consistent with the known deleterious effects of GC on wound  
284 healing (43) and with pre-clinical evidence of improved healing by 11 $\beta$ -HSD1 inhibition in animal  
285 models of stress, obesity, GC excess and ageing from our group and others (19, 23-25). A recent  
286 study in *db/db* mice also reported increased 11 $\beta$ -HSD1 activity during wound healing compared to  
287 wild-type mice, although this remains to be explored in humans (44). By day 7 post-wounding, there  
288 was no preliminary evidence of an effect. However, this may have been limited by measurement of  
289 maximal clot depth, rather than volume, which should be addressed in future studies. Further, no  
290 granulation tissue was detectable at this time point, consistent with normal progression of healing.

291 To strengthen the case for potential skin benefits of AZD4017, we also found preliminary evidence  
292 that AZD4017 may increase epidermal integrity, an improvement comparable to that of young vs.  
293 aged skin (45). This is supported by studies demonstrating reduced skin integrity following human  
294 psychological stress (46) or exogenous GC treatment (47). In contrast, we previously found increased  
295 epidermal integrity in mice treated with oral corticosterone which was reversed by 11 $\beta$ -HSD1

296 inhibition (23), suggesting epidermal integrity regulation by endogenous GC may be opposed in  
297 humans and mouse, highlighting the importance of our findings.

298 Provisional evidence of a modest impairment in epidermal barrier function and recovery by AZD4017  
299 was also observed in our study. GC are known to both impair and promote epidermal barrier  
300 function, the former predominantly with exogenous GC treatment (47-49) and the latter following  
301 endogenous GC excess (50). Our results indicate for the first time that endogenous cortisol also  
302 promotes epidermal barrier function via 11 $\beta$ -HSD1 in humans.

303 GC have been shown to impair healing through repression of epidermal growth factor signalling that  
304 inhibits keratinocyte re-epithelialisation (essential for wound repair) whilst concomitantly promoting  
305 keratinocyte differentiation to promote barrier function (11). Our differential findings of improved  
306 wound healing and impaired barrier function by AZD4017 are in agreement, although barrier  
307 impairment was more modest. However, future trials exploring possible benefits of 11 $\beta$ -HSD1  
308 inhibition on wound healing should monitor the epidermal barrier, particularly in patients with a  
309 compromised function e.g. atopic dermatitis.

310 Peripheral neuropathy is a serious complication in diabetes. To safeguard against any possible  
311 detrimental effects on nerve function, sudomotor analysis was conducted (51). Nerve function was  
312 unaffected by AZD4017 overall and in the hands. At the lowest level of confidence, a modest  
313 impairment was noted in the feet and therefore, monitoring of nerve function should be included in  
314 future trials to rule out any adverse effects.

315 In this relatively short, preliminary study, there were no significant safety concerns. Overall, eGFR  
316 and other laboratory safety outcomes gave no evidence of a detrimental effect. Indeed conversely,  
317 we found evidence of improvements in some “metabolic” traits, notably high density lipoprotein,  
318 cholesterol and systolic blood pressure in the AZD4017 arm which were not present at baseline or  
319 after 7 days treatment washout (and despite ongoing treatment for these conditions). These  
320 improvements are consistent with results from other selective 11 $\beta$ -HSD1 inhibitor trials (33-36).

321 Importantly, cardiovascular disease markers are a strong predictor of ulcer occurrence, healing,  
322 complications and recurrence (52, 53). Through alleviating cardiovascular disease burden, oral 11 $\beta$ -  
323 HSD1 inhibitors could also reduce ulcer recurrence in high risk patients, but this will require further  
324 clinical investigation with long-term 11 $\beta$ -HSD1 inhibitor therapy. Concomitant medication was not  
325 formally captured in this trial and based on our findings, warrants monitoring in future studies.

326 The use of wounds induced by biopsy, rather than active diabetic ulcers, was a key limitation of our  
327 study design. However, this was necessary to ensure AZD4017 did not raise any safety concerns in  
328 acute wounds and patients with relatively well-managed diabetes before progression to patients  
329 with more severe disease. The small sample size and lack of inferential testing, whilst recommended  
330 for pilot trials, require all putative findings presented here to be confirmed in fully-powered trials. It  
331 is likely that these would have greater resources to support recruitment, which, although target  
332 sample size was achieved, was also a limitation.

333 Our findings make a strong case for a future study in patients with active ulcers where the primary  
334 outcome should be an established measure of ulcer healing. Given that approximately 5% of patients  
335 with type 2 diabetes have a diabetic foot ulcer, a future confirmatory trial will likely be multi-centre.

336 Stratification of randomisation by key variables known to affect 11 $\beta$ -HSD1 function (e.g. age) and  
337 wound healing (e.g. infection / ulcer size at presentation) is also advisable. Between-group  
338 differences were strongest following 28 days of AZD4017 treatment. Therefore, a future study  
339 schedule could be simplified and coordinated with routine appointments to improve recruitment.

340 Although requiring confirmation, improvements in healing, skin integrity and metabolic risk factors  
341 of ulcer recurrence hold promise for 11 $\beta$ -HSD1 as a novel therapeutic target in wound repair. A fully-  
342 powered clinical trial in patients with active ulcers and type 2 diabetes mellitus is now warranted.

## 343 **Materials and Methods**

344 The final approved trial Protocol v2.0 24th October 2018 is provided in Appendix 2.

### 345 **Study Design**

346 This was a randomised, double-blind and parallel group, placebo-controlled, phase II pilot trial in  
347 patients with T2DM. Participants were recruited between 28<sup>th</sup> March 2018 and 23<sup>rd</sup> January 2019  
348 (first to last randomised participant telephone invitations) with last participant last follow-up  
349 (telephone discharge) on 3<sup>rd</sup> April 2019. A total of 28 participants (22 male, 6 female) were  
350 randomised and 27 completed the 35 day oral AZD4017 or placebo treatment. For study design  
351 details, please refer to section 5 of Appendix 2.

### 352 **Selection of sample size**

353 Published guidance for pilot studies recommended a sample size of 12 participants per arm  
354 completing the protocol (54). To ensure this minimum number completed the protocol, the study  
355 aimed to randomise 15 per arm to allow for 20% drop-out. Please refer to section 13.9 in Appendix 2  
356 for details.

### 357 **Consent, Ethical Approval and Oversight**

358 Informed consent was obtained after the nature and possible consequences of the study had been  
359 explained. Full ethical approval was acquired prior to onset of recruitment from North West Greater  
360 Manchester Central Research Ethics Committee 17/NW/0283.

361 Data monitoring was carried out during the trial by the study management team and the sponsor.  
362 Independent oversight of the study including interim safety monitoring was conducted by an  
363 Independent Data Monitoring and Ethics Committee.

### 364 **Randomisation and blinding**

365 The randomisation process is described in section 6.4.3 of Appendix 1. Blinding procedures included  
366 participants and the study team being blinded to the randomisation process, mitigation of accidental  
367 unblinding, semi-blind interim safety analyses and independent Data Monitoring and Ethics  
368 Committee oversight. Dosing compliance was monitored by self-reported completion of diary cards  
369 and by counting the number of tablets remaining at each study visit (see Materials and Methods).  
370 Further detail is provided in section 7 of Appendix 2.

### 371 **Treatments and withdrawal criteria**

372 Participants received either oral AZD4017 (400mg) or matched oral placebo, twice daily for 35 days.  
373 For full treatment and compliance details please see section 8 of Appendix 2. AZD4017 withdrawal  
374 criteria are detailed in section 6.5 of Appendix 2.

### 375 **Study endpoints**

376 The primary endpoint was 24hr 11 $\beta$ -HSD1 activity in skin (efficacy) at baseline and day 28. Secondary  
377 endpoints were systemic 11 $\beta$ -HSD1 activity at baseline and day 35 and AZD4017 quantification in  
378 skin at day 28 and plasma at day 35 (to support efficacy), safety variables at baseline and days 7, 28  
379 and 35, blood pressure, blood safety variables, ECG and biopsy inspection at day 42, urinary cortisol  
380 to cortisone metabolite analysis at baseline and day 35 (to assess systemic GC levels), skin function  
381 variables at baseline and days 2, 7, 28, 30 and 35 and feasibility variables at throughout the study.  
382 Further details are provided in sections 4, 9 and 10 of Appendix 2.

### 383 **Statistical Methods**

384 A standalone statistical analysis plan (SAP) was developed and finalised prior to breaking of the blind  
385 and processing of primary outcome samples.

386 In this pilot study, the analysis was descriptive throughout and hence no specific inferential  
387 hypotheses were formally tested. Analysis followed published recommendations which state that in  
388 pilot trials the focus should be on descriptive statistics and estimation, using a range of confidence  
389 intervals (CIs) other than 95% confidence, and interpreting these with regards to the minimum  
390 clinically important difference (MCID)(55). As MCIDs have not been established in this patient group  
391 for the outcomes under investigation, we have converted the CI limits into % difference relative to  
392 the mean or median in the placebo group as a guideline when reporting results. Analyses were  
393 conducted in Stata 16.1 (StataCorp 2019. College Station, TX). For further details please refer to  
394 section 13 of Appendix 2 and Appendix 3.

### 395 **References and Notes**

- 396 1. C. K. Sen, G. M. Gordillo, S. Roy, R. Kirsner, L. Lambert, T. K. Hunt, F. Gottrup, G. C. Gurtner,  
397 M. T. Longaker, Human skin wounds: a major and snowballing threat to public health and  
398 the economy. *Wound repair and regeneration : official publication of the Wound Healing  
399 Society [and] the European Tissue Repair Society* **17**, 763-771 (2009).
- 400 2. F. Gottrup, J. Apelqvist, P. Price, G. European Wound Management Association Patient  
401 Outcome, Outcomes in controlled and comparative studies on non-healing wounds:  
402 recommendations to improve the quality of evidence in wound management. *Journal of  
403 wound care* **19**, 237-268 (2010).
- 404 3. K. R. Vowden, P. Vowden, A survey of wound care provision within one English health care  
405 district. *Journal of tissue viability* **18**, 2-6 (2009).
- 406 4. K. Vowden, P. Vowden, J. Posnett, The resource costs of wound care in Bradford and  
407 Airedale primary care trust in the UK. *Journal of wound care* **18**, 93-94, 96-98, 100 passim  
408 (2009).
- 409 5. N. Hex, C. Bartlett, D. Wright, M. Taylor, D. Varley, Estimating the current and future costs of  
410 Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and  
411 productivity costs. *Diabetic medicine : a journal of the British Diabetic Association* **29**, 855-  
412 862 (2012).
- 413 6. J. R. Sowers, H. R. Lippman, Cushing's syndrome due to ectopic ACTH production: cutaneous  
414 manifestations. *Cutis* **36**, 351-352, 354 (1985).

- 415 7. P. Autio, A. Oikarinen, J. Melkko, J. Risteli, L. Risteli, Systemic glucocorticoids decrease the  
416 synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment  
417 has little effect. *The British journal of dermatology* **131**, 660-663 (1994).
- 418 8. V. P. Werth, A. M. Kligman, X. Shi, A. Pagnoni, Lack of correlation of skin thickness with bone  
419 density in patients receiving chronic glucocorticoid. *Archives of dermatological research* **290**,  
420 388-393 (1998).
- 421 9. H. C. Korting, A. Unholzer, M. Schafer-Korting, I. Tausch, J. Gassmueller, K. H. Nietsch,  
422 Different skin thinning potential of equipotent medium-strength glucocorticoids. *Skin*  
423 *pharmacology and applied skin physiology* **15**, 85-91 (2002).
- 424 10. P. Nuutinen, R. Rieki, M. Parikka, T. Salo, P. Autio, J. Risteli, A. Oikarinen, Modulation of  
425 collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone  
426 in human skin. *The British journal of dermatology* **148**, 39-45 (2003).
- 427 11. B. Lee, C. Vouthounis, O. Stojadinovic, H. Brem, M. Im, M. Tomic-Canic, From an  
428 enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF  
429 leads to inhibition of wound healing. *Journal of molecular biology* **345**, 1083-1097 (2005).
- 430 12. S. Schoepe, H. Schacke, E. May, K. Asadullah, Glucocorticoid therapy-induced skin atrophy.  
431 *Experimental dermatology* **15**, 406-420 (2006).
- 432 13. K. M. Aberg, K. A. Radek, E. H. Choi, D. K. Kim, M. Demerjian, M. Hupe, J. Kerbleski, R. L.  
433 Gallo, T. Ganz, T. Mauro, K. R. Feingold, P. M. Elias, Psychological stress downregulates  
434 epidermal antimicrobial peptide expression and increases severity of cutaneous infections in  
435 mice. *The Journal of clinical investigation* **117**, 3339-3349 (2007).
- 436 14. S. E. Lee, J. M. Kim, M. K. Jeong, C. C. Zouboulis, S. H. Lee, 11beta-hydroxysteroid  
437 dehydrogenase type 1 is expressed in human sebaceous glands and regulates glucocorticoid-  
438 induced lipid synthesis and toll-like receptor 2 expression in SZ95 sebocytes. *The British*  
439 *journal of dermatology* **168**, 47-55 (2013).
- 440 15. R. G. Albuquerque, M. A. Rocha, E. Bagatin, S. Tufik, M. L. Andersen, Could adult female acne  
441 be associated with modern life? *Archives of dermatological research* **306**, 683-688 (2014).
- 442 16. S. Roy, S. Khanna, P. E. Yeh, C. Rink, W. B. Malarkey, J. Kiecolt-Glaser, B. Laskowski, R. Glaser,  
443 C. K. Sen, Wound site neutrophil transcriptome in response to psychological stress in young  
444 men. *Gene expression* **12**, 273-287 (2005).
- 445 17. P. T. Marucha, J. K. Kiecolt-Glaser, M. Favagehi, Mucosal wound healing is impaired by  
446 examination stress. *Psychosomatic medicine* **60**, 362-365 (1998).
- 447 18. S. A. Morgan, E. L. McCabe, L. L. Gathercole, Z. K. Hassan-Smith, D. P. Lerner, I. J. Bujalska, P.  
448 M. Stewart, J. W. Tomlinson, G. G. Lavery, 11beta-HSD1 is the major regulator of the tissue-  
449 specific effects of circulating glucocorticoid excess. *Proceedings of the National Academy of*  
450 *Sciences of the United States of America* **111**, E2482-2491 (2014).
- 451 19. A. Tiganescu, A. A. Tahrani, S. A. Morgan, M. Otranto, A. Desmouliere, L. Abrahams, Z.  
452 Hassan-Smith, E. A. Walker, E. H. Rabbitt, M. S. Cooper, K. Amrein, G. G. Lavery, P. M.  
453 Stewart, 11beta-Hydroxysteroid dehydrogenase blockade prevents age-induced skin  
454 structure and function defects. *The Journal of clinical investigation* **123**, 3051-3060 (2013).
- 455 20. A. Tiganescu, E. A. Walker, R. S. Hardy, A. E. Mayes, P. M. Stewart, Localization, age- and site-  
456 dependent expression, and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in  
457 skin. *The Journal of investigative dermatology* **131**, 30-36 (2011).
- 458 21. G. Hirasawa, H. Sasano, K. Takahashi, K. Fukushima, T. Suzuki, N. Hiwatashi, T. Toyota, Z. S.  
459 Krozowski, H. Nagura, Colocalization of 11 beta-hydroxysteroid dehydrogenase type II and  
460 mineralocorticoid receptor in human epithelia. *The Journal of clinical endocrinology and*  
461 *metabolism* **82**, 3859-3863 (1997).
- 462 22. A. Tiganescu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Increased  
463 glucocorticoid activation during mouse skin wound healing. *The Journal of endocrinology*  
464 **221**, 51-61 (2014).

- 465 23. A. Tiganescu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Topical 11 beta-  
466 Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic  
467 Glucocorticoid Excess in Female Mice. *Endocrinology* **159**, 547-556 (2018).
- 468 24. M. Terao, H. Murota, A. Kimura, A. Kato, A. Ishikawa, K. Igawa, E. Miyoshi, I. Katayama,  
469 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a  
470 candidate target for promoting tissue repair. *PLoS one* **6**, e25039 (2011).
- 471 25. J. K. Youm, K. Park, Y. Uchida, A. Chan, T. M. Mauro, W. M. Holleran, P. M. Elias, Local  
472 blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in  
473 cutaneous wound healing. *Wound repair and regeneration : official publication of the*  
474 *Wound Healing Society [and] the European Tissue Repair Society* **21**, 715-722 (2013).
- 475 26. K. E. Chapman, A. E. Coutinho, Z. Zhang, T. Kipari, J. S. Savill, J. R. Seckl, Changing  
476 glucocorticoid action: 11beta-hydroxysteroid dehydrogenase type 1 in acute and chronic  
477 inflammation. *The Journal of steroid biochemistry and molecular biology* **137**, 82-92 (2013).
- 478 27. S. Itoi, M. Terao, H. Murota, I. Katayama, 11beta-Hydroxysteroid dehydrogenase 1  
479 contributes to the pro-inflammatory response of keratinocytes. *Biochemical and biophysical*  
480 *research communications* **440**, 265-270 (2013).
- 481 28. I. D. Ignatova, R. M. Kostadinova, C. E. Goldring, A. R. Nawrocki, F. J. Frey, B. M. Frey, Tumor  
482 necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression  
483 by CCAAT/enhancer binding protein-beta in HepG2 cells. *American journal of physiology.*  
484 *Endocrinology and metabolism* **296**, E367-377 (2009).
- 485 29. M. S. Bitar, Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. *The*  
486 *American journal of pathology* **152**, 547-554 (1998).
- 487 30. A. Steptoe, R. A. Hackett, A. I. Lazzarino, S. Bostock, R. La Marca, L. A. Carvalho, M. Hamer,  
488 Disruption of multisystem responses to stress in type 2 diabetes: Investigating the dynamics  
489 of allostatic load. *Proceedings of the National Academy of Sciences of the United States of*  
490 *America* **111**, 15693-15698 (2014).
- 491 31. K. Kaur, R. Hardy, M. M. Ahasan, M. Eijken, J. P. van Leeuwen, A. Filer, A. M. Thomas, K.  
492 Raza, C. D. Buckley, P. M. Stewart, E. H. Rabbitt, M. Hewison, M. S. Cooper, Synergistic  
493 induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids:  
494 implications for inflammation associated bone loss. *Annals of the rheumatic diseases* **69**,  
495 1185-1190 (2010).
- 496 32. L. L. Gathercole, G. G. Lavery, S. A. Morgan, M. S. Cooper, A. J. Sinclair, J. W. Tomlinson, P. M.  
497 Stewart, 11beta-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects.  
498 *Endocrine reviews* **34**, 525-555 (2013).
- 499 33. J. Rosenstock, S. Banarer, V. A. Fonseca, S. E. Inzucchi, W. Sun, W. Yao, G. Hollis, R. Flores, R.  
500 Levy, W. V. Williams, J. R. Seckl, R. Huber, I. P. Investigators, The 11-beta-hydroxysteroid  
501 dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2  
502 diabetes inadequately controlled by metformin monotherapy. *Diabetes care* **33**, 1516-1522  
503 (2010).
- 504 34. P. U. Feig, S. Shah, A. Hermanowski-Vosatka, D. Plotkin, M. S. Springer, S. Donahue, C. Thach,  
505 E. J. Klein, E. Lai, K. D. Kaufman, Effects of an 11beta-hydroxysteroid dehydrogenase type 1  
506 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.  
507 *Diabetes, obesity & metabolism* **13**, 498-504 (2011).
- 508 35. S. Shah, A. Hermanowski-Vosatka, K. Gibson, R. A. Ruck, G. Jia, J. Zhang, P. M. Hwang, N. W.  
509 Ryan, R. B. Langdon, P. U. Feig, Efficacy and safety of the selective 11beta-HSD-1 inhibitors  
510 MK-0736 and MK-0916 in overweight and obese patients with hypertension. *Journal of the*  
511 *American Society of Hypertension : JASH* **5**, 166-176 (2011).
- 512 36. R. S. Hardy, H. Botfield, K. Markey, J. L. Mitchell, Z. Alimajstorovic, C. S. J. Westgate, M.  
513 Sagmeister, R. J. Fairclough, R. S. Ottridge, A. Yiangou, K. H. Storbeck, A. E. Taylor, L. C.  
514 Gilligan, W. Arlt, P. M. Stewart, J. W. Tomlinson, S. P. Mollan, G. G. Lavery, A. J. Sinclair,

- 515 11betaHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in  
516 Idiopathic Intracranial Hypertension. *J Clin Endocrinol Metab* **106**, 174-187 (2021).
- 517 37. D. Schwab, C. Sturm, A. Portron, S. Fuerst-Recktenwald, D. Hainzl, P. Jordan, W. C. Stewart,  
518 M. E. Tepedino, H. DuBiner, Oral administration of the 11beta-hydroxysteroid-  
519 dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive,  
520 randomised, placebo-controlled clinical study. *BMJ Open Ophthalmol* **1**, e000063 (2017).
- 521 38. T. Heise, L. Morrow, M. Hompesch, H. U. Haring, C. Kapitza, M. Abt, M. Ramsauer, M. C.  
522 Magnone, S. Fuerst-Recktenwald, Safety, efficacy and weight effect of two 11beta-HSD1  
523 inhibitors in metformin-treated patients with type 2 diabetes. *Diabetes, obesity &*  
524 *metabolism* **16**, 1070-1077 (2014).
- 525 39. S. Freude, T. Heise, H. J. Woerle, A. Jungnik, T. Rauch, B. Hamilton, C. Scholch, F. Huang, U.  
526 Graefe-Mody, Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective  
527 11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose  
528 tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.  
529 *Diabetes Obes Metab* **18**, 483-490 (2016).
- 530 40. M. S. Sagmeister, A. E. Taylor, A. Fenton, N. A. Wall, D. Chanouzas, P. G. Nightingale, C. J.  
531 Ferro, W. Arlt, P. Cockwell, R. S. Hardy, L. Harper, Glucocorticoid activation by 11beta-  
532 hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in  
533 chronic kidney disease: A cross-sectional study. *Clinical endocrinology* **90**, 241-249 (2019).
- 534 41. M. Palermo, C. H. Shackleton, F. Mantero, P. M. Stewart, Urinary free cortisone and the  
535 assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. *Clinical endocrinology*  
536 **45**, 605-611 (1996).
- 537 42. N. S. Greaves, B. Benatar, S. Whiteside, T. Alonso-Rasgado, M. Baguneid, A. Bayat, Optical  
538 coherence tomography: a reliable alternative to invasive histological assessment of acute  
539 wound healing in human skin? *Br J Dermatol* **170**, 840-850 (2014).
- 540 43. E. Harris, A. Tiganescu, S. Tubeuf, S. L. Mackie, The prediction and monitoring of toxicity  
541 associated with long-term systemic glucocorticoid therapy. *Current rheumatology reports*  
542 **17**, 513 (2015).
- 543 44. C. B. Brazel, J. C. Simon, J. P. Tuckermann, A. Saalbach, Inhibition of 11beta-HSD1 Expression  
544 by Insulin in Skin: Impact for Diabetic Wound Healing. *J Clin Med* **9**, (2020).
- 545 45. R. Ghadially, B. E. Brown, S. M. Sequeira-Martin, K. R. Feingold, P. M. Elias, The aged  
546 epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in  
547 humans and a senescent murine model. *The Journal of clinical investigation* **95**, 2281-2290  
548 (1995).
- 549 46. S. J. Choe, D. Kim, E. J. Kim, J. S. Ahn, E. J. Choi, E. D. Son, T. R. Lee, E. H. Choi, Psychological  
550 Stress Deteriorates Skin Barrier Function by Activating 11beta-Hydroxysteroid  
551 Dehydrogenase 1 and the HPA Axis. *Sci Rep* **8**, 6334 (2018).
- 552 47. J. S. Kao, J. W. Fluhr, M. Q. Man, A. J. Fowler, J. P. Hachem, D. Crumrine, S. K. Ahn, B. E.  
553 Brown, P. M. Elias, K. R. Feingold, Short-term glucocorticoid treatment compromises both  
554 permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal  
555 lipid synthesis accounts for functional abnormalities. *The Journal of investigative*  
556 *dermatology* **120**, 456-464 (2003).
- 557 48. L. Kolbe, A. M. Kligman, V. Schreiner, T. Stoudemayer, Corticosteroid-induced atrophy and  
558 barrier impairment measured by non-invasive methods in human skin. *Skin research and*  
559 *technology : official journal of International Society for Bioengineering and the Skin* **7**, 73-77  
560 (2001).
- 561 49. S. K. Ahn, H. N. Bak, B. D. Park, Y. H. Kim, J. K. Youm, E. H. Choi, S. P. Hong, S. H. Lee, Effects  
562 of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier  
563 impairment. *The Journal of dermatology* **33**, 80-90 (2006).
- 564 50. T. K. Lin, M. Q. Man, J. L. Santiago, T. C. Scharschmidt, M. Hupe, G. Martin-Ezquerria, J. K.  
565 Youm, Y. Zhai, C. Trullas, K. R. Feingold, P. M. Elias, Paradoxical benefits of psychological

- 566 stress in inflammatory dermatoses models are glucocorticoid mediated. *The Journal of*  
567 *investigative dermatology* **134**, 2890-2897 (2014).
- 568 51. A. I. Vinik, M. L. Nevoret, C. Casellini, The New Age of Sudomotor Function Testing: A  
569 Sensitive and Specific Biomarker for Diagnosis, Estimation of Severity, Monitoring  
570 Progression, and Regression in Response to Intervention. *Frontiers in endocrinology* **6**, 94  
571 (2015).
- 572 52. D. G. Armstrong, A. J. M. Boulton, S. A. Bus, Diabetic Foot Ulcers and Their Recurrence. *N*  
573 *Engl J Med* **376**, 2367-2375 (2017).
- 574 53. M. J. Young, J. E. McCardle, L. E. Randall, J. I. Barclay, Improved survival of diabetic foot ulcer  
575 patients 1995-2008: possible impact of aggressive cardiovascular risk management. *Diabetes*  
576 *Care* **31**, 2143-2147 (2008).
- 577 54. S. A. Julious, Sample size of 12 per group rule of thumb for a pilot study. *Pharm Stat* **4**, 287-  
578 291 (2005).
- 579 55. E. C. Lee, A. L. Whitehead, R. M. Jacques, S. A. Julious, The statistical interpretation of pilot  
580 trials: should significance thresholds be reconsidered? *Bmc Med Res Methodol* **14**, (2014).

581

## 582 **Acknowledgements**

583 **Funding:** This work was supported by an MRC Confidence in Concept Award (MC\_PC\_15046) to Ana  
584 Tiganescu, the NIHR Leeds Biomedical Research Centre, NIHR Leeds In vitro Diagnostic Evidence Co-  
585 operative and NIHR Senior Investigator Award to Paul Stewart (NF-SI-0514-10090). **Author**  
586 **contributions:** Ramzi Ajjan: Conceptualization, Methodology, Investigation, Writing - Review &  
587 Editing, Resources, Supervision (joint), Elizabeth Hensor: Software, Formal analysis, Data Curation,  
588 Writing - Review & Editing, Visualization, Kave Shams: Investigation, Francesco Del Galdo:  
589 Investigation, Afroze Abbas: Investigation, Janet Woods: Investigation, Ann Morgan: Supervision  
590 (supporting), Writing - Review & Editing, Paul M Stewart: Conceptualization, Funding acquisition,  
591 Writing - Review & Editing, Rebecca Fairclough: Resources, Supervision (supporting), Lorraine  
592 Webber: Resources, Supervision (supporting), Lindsay Pegg: Resources, Supervision (supporting),  
593 Adrian Freeman: Writing - Review & Editing, Resources, Supervision (supporting), Angela E Taylor:  
594 Investigation, Wiebke Arlt: Methodology, Abd Tahrani: Conceptualization, Writing - Review &  
595 Editing, David Russell: Investigation, Supervision (supporting) and Ana Tiganescu: Conceptualization  
596 (lead), Funding acquisition (lead), Investigation (lead), Methodology (lead), Project administration  
597 (lead), Supervision (joint), Validation, Writing - Original Draft, Writing - Review & Editing. **Competing**  
598 **interests:** nothing to disclose. **Data and materials availability:** All data associated with this study are  
599 available in the main text or the supplementary materials. **Trial registration:** International Standard  
600 Randomised Controlled Trial Number 74621291 [www.isrctn.com/ISRCTN74621291](http://www.isrctn.com/ISRCTN74621291). ClinicalTrials.gov  
601 Identifier: NCT03313297 <https://clinicaltrials.gov/ct2/show/NCT03313297>.

602 This paper presents independent research supported by the National Institute for Health Research  
603 (NIHR) Leeds Biomedical Research Centre (BRC). The views expressed are those of the authors and  
604 not necessarily those of the NIHR or the Department of Health and Social Care.

## 605 **Figure Captions**

### 606 **Figure 1 CONSORT flow diagram**

607 Progress, from screening through to study completion, of participants in the double-blind  
608 randomised placebo-controlled trial testing a 35 day oral AZD4017 treatment versus placebo in



609 adults with type 2 diabetes. A total of 300 prospective participants were screened. Eight of the 36  
610 individuals enrolled in the study were not randomised owing to not meeting eligibility criteria. 27 out  
611 of 28 participants who were randomised completed the study.

### 612 **Figure 2 Efficacy outcome measures**

613 Adjusted differences between placebo (PCB) and AZD4017 (AZD) groups in absolute values of  
614 primary and secondary efficacy outcomes in the full analysis set. Box plots of observed values (left  
615 panel) and adjusted differences between medians estimated in imputed data (right panel) are  
616 presented. Solid lines indicate no difference between groups (=0). Dotted lines indicate 20%  
617 improvement relative to the median PCB (not applicable to F/E ratio).

### 618 **Figure 3 Skin outcome measures**

619 (a-b, d-g) Adjusted differences between placebo (PCB) and AZD4017 (AZD) groups in absolute values  
620 of secondary efficacy outcomes in the full analysis set. Error bar plots of observed values (indicating  
621 90% CIs; left panel) and adjusted differences between means estimated in imputed data (right panel)  
622 are presented. TEWL and integrity readings were log-transformed prior to analysis therefore  
623 geometric means and ratios have been provided for these variables. Solid lines indicate no  
624 difference between groups (=0 for WH, =1 for TEWL and integrity). Dotted lines indicate 20%  
625 improvement relative to the mean in PCB.

626 (c) Representative wound healing OCT images at day 2 (2 days post-biopsy and 2 days of AZD4017  
627 treatment). Maximal early granulation tissue width (arrow) was measured for participants treated  
628 with placebo (left panel) or AZD4017 (right panel). Wide dashes indicate dermal-epidermal junction.  
629 Epidermis = e. Dermis = d. Granulation tissue = gt Scale bar = 250µm.

### 630 **Figure 4 Safety**

631 Displays of longitudinal laboratory safety data. Population: Safety set. ULN = upper limit of normal;  
632 LLN = lower limit of normal (where applicable).

## 633 **Table Captions**

### 634 **Table 1**

635 Baseline demographics, primary and secondary efficacy variables, laboratory safety variables.  
636 Population: Full analysis set.

### 637 **Table 2**

638 Primary and secondary efficacy outcomes; adjusted differences between treatment groups.  
639 Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues  
640 with the data distributions, for all variables except TEWL, integrity, wound diameter & depth,  
641 median regression was used to estimate confidence intervals around differences between the  
642 groups. For TEWL, integrity, wound depth and diameter, linear regression was used. TEWL and  
643 integrity measurements were log-transformed prior to analysis; differences have been expressed as  
644 ratios of geometric means (AZD:PCB). For each variable, the comparison was adjusted for baseline  
645 value of the variable (not applicable to wound diameter & depth), age, sex and baseline HbA1c. All  
646 TEWL readings were adjusted using TEWL baseline at day 0. Between group differences were not  
647 calculated for biopsy and plasma AZD4017 because available PCB values did not vary, all were below  
648 the detection limit.

649 **Table 3**

650 Longitudinal laboratory safety variables; adjusted differences between treatment groups.  
651 Population: Safety set. All point estimates and confidence intervals estimated via linear regression.

652 **Table 4**

653 Adverse event summary. Population: Safety set.

654 **Supplementary Material**

655 Table S1. Full descriptive data for primary and secondary efficacy variables. Population: Full analysis  
656 set.

657 Table S2. Full descriptive data for laboratory safety variables. Population: Safety set.

658 Table S3. IMP (placebo or AZD4017) compliance. Population: Full analysis set.

659 Figure S1. Correlation between AZD4017 levels in the biopsy taken at day 28 and in plasma taken at  
660 day 35. Population: Full analysis set (AZD4017 group only).

661 Table S4. Primary and secondary efficacy outcomes; unadjusted differences in final values between  
662 treatment groups. Population: Full analysis set. Multiple imputation was used to address missing  
663 data. Due to issues with the data distributions, for all variables except TEWL, integrity, wound  
664 diameter & depth, median regression was used to estimate confidence intervals around differences  
665 between the groups. For TEWL, integrity, wound depth and diameter, linear regression was used.  
666 TEWL and integrity measurements were log-transformed prior to analysis; differences have been  
667 expressed as ratios of geometric means (AZD:PCB).

668 Table S5. Sensitivity analysis of primary and secondary efficacy outcomes re-imputed after QC fails  
669 and outliers removed. Population: Full analysis set. Sensitivity analysis. Data were re-imputed after  
670 deleting two baseline radioassays which failed QC and one outlying ELISA assay result at day 28,  
671 TEWL readings that were potentially unreliable due to high temperatures and TEWL and WH  
672 measures which were collected earlier than scheduled. For each variable, the comparison was  
673 adjusted for baseline value of the variable (where applicable; not applicable to wound diameter &  
674 depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using TEWL baseline at day 0.

675 Figure S2. Correlation between the different methods of assessing 24hr 11bHSD1 activity (%  
676 conv/24hr). Population: Full analysis set.

677 Table S6: Unadjusted differences in changes from baseline in primary and secondary efficacy  
678 outcomes. Population: Full analysis set. Multiple imputation was used to address missing data. Due  
679 to issues with the data distributions, for all variables except TEWL & integrity, median regression was  
680 used to estimate confidence intervals around differences between the groups. For TEWL & integrity,  
681 linear regression was used. TEWL and integrity measurements were log-transformed prior to  
682 analysis. For these variables changes from baseline have been expressed as ratios of follow-up  
683 measurements to baseline values; between-group differences have been expressed as ratios of  
684 geometric means (AZD:PCB).

685 Table S7: Adjusted differences in changes from baseline in primary and secondary efficacy outcomes.  
686 Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues  
687 with the data distributions, for all variables except TEWL & integrity, median regression was used to  
688 estimate confidence intervals around differences between the groups. For TEWL & integrity, linear  
689 regression was used. TEWL and integrity measurements were log-transformed prior to analysis. For  
690 these variables changes from baseline have been expressed as ratios of follow-up measurements to  
691 baseline values; between-group differences have been expressed as ratios of geometric means  
692 (AZD:PCB). For each variable, the comparison was adjusted for baseline value of the variable, age,  
693 sex and baseline HbA1c.

694 Table S8: Sensitivity analysis of trans-epidermal water loss (TEWL) adjusting for exact timing of post-  
695 disruption measurements. Population: Full analysis set. Analysis models included exact  
696 measurement times to account for variation in timings; results have been provided for a) data  
697 imputed including all observed values and b) data re-imputed after deleting TEWL readings that  
698 were potentially unreliable due to high temperatures. Linear mixed models were used to model  
699 post-baseline TEWL readings (within each set) as a function of time since disruption. Quadratic  
700 functions were added to allow for nonlinear change over time. Baseline values and changes over  
701 time were permitted to vary between patients. TEWL measurements were log-transformed prior to  
702 analysis; differences have been expressed as ratios of geometric means (AZD:PCB). For each variable,  
703 the comparison was adjusted for baseline (day 0, hour 0) TEWL, age, sex and baseline HbA1c.

704 Table S9. Sensitivity analysis of primary and secondary efficacy outcomes in available case data.  
705 Population: Full analysis set. Due to issues with the data distributions, for all variables except TEWL,  
706 integrity, wound diameter & depth, quantile (median) regression was used to obtain point estimates  
707 and confidence intervals for differences between groups. For TEWL, integrity, wound depth and  
708 diameter, linear regression was used. TEWL and integrity measurements were log-transformed prior  
709 to analysis; differences have been expressed as ratios of geometric means (AZD:PBO). For each  
710 variable, the comparison was adjusted for baseline value of the variable (where applicable; not  
711 applicable to wound diameter & depth), age, sex and baseline HbA1c. All TEWL readings were  
712 adjusted using TEWL baseline at day 0.

713 Table S10. Sensitivity analysis of primary and secondary efficacy outcomes using last observation  
714 carried forward. Population: Full analysis set. Due to issues with the data distributions, for all  
715 variables except TEWL, integrity, wound diameter & depth, quantile (median) regression was used to  
716 obtain point estimates and confidence intervals for differences between groups. For TEWL, integrity,  
717 wound depth and diameter, linear regression was used. TEWL and integrity measurements were log-  
718 transformed prior to analysis; differences have been expressed as ratios of geometric means  
719 (AZD:PBO). For each variable, the comparison was adjusted for baseline value of the variable (where  
720 applicable; not applicable to wound diameter & depth), age, sex and baseline HbA1c. All TEWL  
721 readings were adjusted using TEWL baseline at day 0. Note that day 0 TEWL measurements were  
722 missed in error for 1 patient therefore data could only be carried forward for 27 patients.

723 Table S11. Correlations between AZD4017 compliance and efficacy outcomes. Population: Full  
724 analysis set (AZD group only). Absolute rho values  $\geq 0.3$  were considered preliminary evidence of  
725 association. Sensitivity analysis excluded baseline radioimmunoassay samples that failed QC, an  
726 outlying ELISA assay result at day 28, TEWL readings recorded on very hot days, and results that

727 were recorded 1 day earlier than planned, prior to imputation. Note that not all of these issues  
728 occurred in samples from the AZD group but could have altered imputed values for any incomplete  
729 variables.

730 Table S12. Unadjusted differences in final values of longitudinal laboratory safety variables.  
731 Population: Safety set. Multiple imputation was used to address missing data. All point estimates  
732 and confidence intervals estimated via linear regression.

733 Table S13. Unadjusted differences in changes from baseline in longitudinal laboratory safety  
734 variables. Population: Safety set. Multiple imputation was used to address missing data. All point  
735 estimates and confidence intervals estimated via linear regression.

736 Table S14. Adjusted differences in changes from baseline in longitudinal laboratory safety variables.  
737 Population: Safety set. Multiple imputation was used to address missing data. All point estimates  
738 and confidence intervals estimated via linear regression.

739 Table S15. Longitudinal laboratory safety variables; absolute and relative frequencies of values  
740 below or above normal limits. Population: Safety set

741 Table S16. Sample sizes for future trials. Based on estimates from available case data in full analysis  
742 set. At  $\alpha=0.05$  (5% significance),  $1-\text{Beta}=0.90$  (90% power), accounting for 10% drop-out, sample  
743 sizes for a range of substantive between-group differences are presented below. For TEWL and  
744 integrity variables, means and SDs are presented on the log scale. Note that for all variables, sample  
745 size has been based on mean and SD (and Pearson's  $r$  where applicable), as specified in the statistical  
746 analysis plan; issues with distributions for some variables may reduce the accuracy of these  
747 estimates. Sample sizes presented here should be considered preliminary.

Figure 1




Figure 2





Figure 3

















Figure 4



i)



**Table 1: Baseline demographics, primary and secondary efficacy variables, laboratory safety variables.**

Population: Full analysis set.

Variable	Summary	PCB	AZD	Total
		N=14	N=14	N=28
Age	Mean (SD), range	60.3 (13.4), 31.0 to 84.0	60.1 (14.5), 28.0 to 75.0	60.2 (13.7), 28.0 to 84.0
Male	n/N (%)	12/14 (86)	10/14 (71)	22/28 (79)
11bHSD1 activity radioassay (% conv/24hrs)	Median (Q1, Q3)	15.3 (11.6, 18.4)	10.7 (9.4, 17.4)	13.6 (9.8, 17.9)
11bHSD1 activity ELISA (% conv/24hrs)	Median (Q1, Q3)	6.8 (5.5, 15.6)	6.4 (4.2, 8.5)	6.8 (4.8, 10.7)
Sudomotor function Left Hand (micro S)	Median (Q1, Q3)	54.0 (47.0, 63.0)	57.5 (39.0, 71.0)	56.0 (46.5, 68.5)
Sudomotor function Right Hand (micro S)	Median (Q1, Q3)	54.0 (47.0, 60.0)	56.5 (41.0, 67.0)	56.0 (45.5, 61.5)
Sudomotor function Hands (micro S)	Median (Q1, Q3)	53.8 (48.0, 60.5)	56.8 (40.0, 70.5)	56.8 (47.3, 65.0)
Sudomotor function Left Foot (micro S)	Median (Q1, Q3)	65.5 (46.0, 78.0)	79.0 (63.0, 84.0)	74.5 (57.0, 81.5)
Sudomotor function Right Foot (micro S)	Median (Q1, Q3)	69.5 (48.0, 79.0)	77.0 (69.0, 82.0)	74.0 (54.5, 79.0)
Sudomotor function Feet (micro S)	Median (Q1, Q3)	67.5 (44.5, 76.5)	78.0 (64.0, 83.5)	75.0 (55.8, 79.8)
Sudomotor function Overall (micro S)	Median (Q1, Q3)	61.0 (46.8, 67.8)	66.6 (63.3, 71.3)	64.6 (50.3, 69.8)
Skin hydration (A.U)	Median (Q1, Q3)	40.5 (34.5, 46.2)	40.4 (36.7, 45.5)	40.5 (36.1, 45.8)
Epidermal thickness (micro m)	Median (Q1, Q3)	62.8 (54.5, 69.2)	65.7 (60.7, 69.3)	63.8 (58.4, 69.3)
Cortisol (mcg/24h)	Median (Q1, Q3)	68.5 (40.0, 101.0)	75.5 (48.0, 84.0)	74.5 (47.5, 94.0)
Urinary [THF+alloTHF]/THE ratio	Median (Q1, Q3)	1.0 (0.8, 1.2)	1.0 (0.8, 1.1)	1.0 (0.8, 1.1)
Hour 0 TEWL (Set 1; Day 0)	Log scale Mean (SD), n Geometric Mean	2.1 (0.4), n=14 8.2	2.2 (0.3), n=13 9.1	2.2 (0.4), n=27 8.6
N tapes required for barrier disruption	Log scale Mean (SD), n Geometric Mean	3.8 (0.4), n=14 44.5	3.9 (0.5), n=13 50.5	3.9 (0.4), n=27 47.5
Body Mass Index (kg / m <sup>2</sup> )	Mean (SD)	33.67 (13.47)	35.05 (5.68)	34.36 (10.17)
Waist-hip ratio	Mean (SD)	0.98 (0.08)	1.03 (0.08)	1.01 (0.08)
Systolic blood pressure (mm Hg)	Mean (SD)	135.71 (21.01)	140.43 (12.02)	138.07 (16.97)
Diastolic blood pressure (mm Hg)	Mean (SD)	83.86 (8.91)	72.64 (9.96)	78.25 (10.89)
HbA1c (mmol/mol)	Mean (SD)	72.29 (19.43)	66.00 (14.91)	69.14 (17.29)
High density lipoprotein (mmol/l)	Mean (SD)	1.24 (0.31)	1.19 (0.27)	1.21 (0.29)
Cholesterol (mmol/l)	Mean (SD)	4.36 (1.13)	3.95 (0.75)	4.15 (0.97)
Triglycerides (mmol/l)	Mean (SD)	1.68 (0.74)	2.02 (1.02)	1.85 (0.89)
Haemoglobin (g/l)	Mean (SD)	139.21 (14.12)	139.43 (11.35)	139.32 (12.57)
White cells (x10 <sup>9</sup> /l)	Mean (SD)	6.46 (2.55)	7.34 (2.04)	6.90 (2.31)
Platelets (x10 <sup>9</sup> /l)	Mean (SD)	218.71 (61.85)	273.14 (81.37)	245.93 (76.15)
Red cells (x10 <sup>12</sup> /l)	Mean (SD)	4.84 (0.49)	4.71 (0.48)	4.78 (0.48)

Variable	Summary	PCB	AZD	Total
		N=14	N=14	N=28
Mean corpuscular volume (fl)	Mean (SD)	88.43 (4.64)	91.21 (6.96)	89.82 (5.98)
Haematocrit (packed cell volume)	Mean (SD)	0.43 (0.04)	0.43 (0.03)	0.43 (0.03)
Mean corpuscular haemoglobin (pg)	Mean (SD)	28.82 (2.09)	29.74 (2.47)	29.28 (2.29)
Corpuscular hemoglobin concentration (g/l)	Mean (SD)	325.57 (10.43)	326.64 (8.29)	326.11 (9.26)
Red blood cell distribution width (%)	Mean (SD)	13.88 (0.98)	14.12 (1.10)	14.00 (1.03)
Albumin (g/l)	Mean (SD)	39.43 (2.56)	39.50 (2.44)	39.46 (2.46)
Bilirubin (umol/l)	Mean (SD)	8.93 (2.97)	8.14 (2.82)	8.54 (2.87)
Alkaline phosphatase (U/l)	Mean (SD)	80.43 (23.76)	85.07 (26.08)	82.75 (24.59)
Alanine aminotransferase (iu/l)	Mean (SD)	24.64 (7.10)	27.43 (10.91)	26.04 (9.14)
Aspartate aminotransferase (iu/l)	Mean (SD)	21.00 (4.95)	22.64 (5.50)	21.82 (5.20)
Gamma-glutamyl transpeptidase (iu/l)	Mean (SD)	41.86 (33.87)	39.29 (29.87)	40.57 (31.37)
eGFR (ml/min/1.73m <sup>2</sup> )	Mean (SD)	81.86 (9.69)	79.21 (13.59)	80.54 (11.66)
Sodium (mmol/l)	Mean (SD)	138.93 (2.06)	140.71 (5.47)	139.82 (4.15)
Potassium (mmol/l)	Mean (SD)	4.46 (0.33)	4.63 (0.41)	4.55 (0.37)
Urea (mmol/l)	Mean (SD)	6.96 (2.81)	7.25 (2.17)	7.10 (2.47)
Creatinine (umol/l)	Mean (SD)	76.64 (15.36)	76.21 (20.04)	76.43 (17.52)
Testosterone (nmol/l)	Mean (SD)	11.10 (6.25)	6.97 (5.48)	9.04 (6.14)
Dehydroepiandrosterone sulphate (umol/l)	Mean (SD)	3.53 (2.19)	2.91 (1.69)	3.22 (1.95)
Free thyroxine (pmol/l)	Mean (SD)	14.86 (2.20)	15.73 (1.58)	15.30 (1.93)
Thyroid stimulating hormone (mIU/l)	Mean (SD)	1.74 (0.66)	1.72 (0.63)	1.73 (0.64)

Nn=Number non-missing; Q1=1st quartile; Q3=3rd quartile

**Table 2: Primary and secondary efficacy outcomes; adjusted differences between treatment groups**

Population: Full analysis set. Multiple imputation was used to address missing data. Due to issues with the data distributions, for all variables except TEWL, integrity, wound diameter & depth, median regression was used to estimate confidence intervals around differences between the groups. For TEWL, integrity, wound depth and diameter, linear regression was used. TEWL and integrity measurements were log-transformed prior to analysis; differences have been expressed as ratios of geometric means (AZD:PCB). For each variable, the comparison was adjusted for baseline value of the variable (not applicable to wound diameter & depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using TEWL baseline at day 0. Between group differences were not calculated for biopsy and plasma AZD4017 because available PCB values did not vary, all were below the detection limit.

Variable	Observed median (Q1, Q3)		Estimated median*		Difference*		Confidence interval*				
	PCB	AZD	PCB N=14	AZD N=14	AZD-PCB	75%	80%	85%	90%	95%	
11bHSD1 activity radioassay (% conv/24hrs): Day 28	12.0 ( 8.9, 14.5), n=13	12.7 ( 8.8, 15.6), n=14	11.8	12.8	1.1	(-2.0, 4.1)	(-2.3, 4.4)	(-2.8, 4.9)	(-3.4, 5.5)	(-4.3, 6.4)	
11bHSD1 activity ELISA (% conv/24hrs): Day 28	5.6 ( 1.0, 7.6), n=13	4.3 ( 3.1, 5.0), n=14	4.9	4.3	-0.5	(-2.8, 1.7)	(-3.0, 2.0)	(-3.4, 2.3)	(-3.8, 2.7)	(-4.5, 3.4)	
Sudomotor function Left Hand (micro S): Day 35	58.0 (48.0, 63.0), n=13	64.0 (59.0, 72.0), n=13	55.3	65.7	10.4	( 2.0, 18.7)	( 1.0, 19.7)	(-0.2, 21.0)	(-1.8, 22.6)	(-4.4, 25.1)	
Sudomotor function Right Hand (micro S): Day 35	55.0 (51.0, 60.0), n=13	63.0 (57.0, 69.0), n=13	55.6	60.6	5.0	(-3.1, 13.1)	(-4.0, 14.0)	(-5.2, 15.2)	(-6.7, 16.8)	(-9.2, 19.2)	
Sudomotor function Hands (micro S): Day 35	57.5 (49.5, 61.0), n=13	63.5 (59.0, 70.5), n=13	55.8	63.0	7.3	(-1.0, 15.6)	(-2.0, 16.5)	(-3.2, 17.7)	(-4.8, 19.3)	(-7.4, 21.9)	
Sudomotor function Left Foot (micro S): Day 35	70.0 (61.0, 76.0), n=13	80.0 (64.0, 82.0), n=13	75.5	68.5	-7.0	(-14.8, 0.8)	(-15.7, 1.7)	(-16.9, 2.8)	(-18.4, 4.3)	(-20.7, 6.7)	
Sudomotor function Right Foot (micro S): Day 35	65.0 (63.0, 75.0), n=13	80.0 (68.0, 82.0), n=13	73.0	68.9	-4.1	(-10.3, 2.2)	(-11.1, 3.0)	(-12.0, 3.9)	(-13.2, 5.1)	(-15.1, 7.0)	
Sudomotor function Feet (micro S): Day 35	68.5 (62.0, 75.0), n=13	80.0 (66.0, 82.5), n=13	73.8	69.3	-4.5	(-11.4, 2.3)	(-12.2, 3.1)	(-13.2, 4.1)	(-14.5, 5.4)	(-16.6, 7.5)	
Sudomotor function Overall (micro S): Day 35	59.8 (53.8, 68.0), n=13	70.8 (64.5, 73.0), n=13	65.0	63.7	-1.3	(-6.8, 4.1)	(-7.4, 4.7)	(-8.2, 5.5)	(-9.2, 6.6)	(-10.9, 8.3)	
Skin hydration (A.U): Day 35	40.5 (29.4, 46.0), n=12	45.3 (37.0, 46.5), n=12	38.0	43.7	5.7	(-0.1, 11.4)	(-0.8, 12.1)	(-1.6, 13.0)	(-2.8, 14.1)	(-4.6, 15.9)	
Epidermal thickness (micro m): Day 35	57.5 (55.7, 67.3), n=13	66.3 (60.6, 74.4), n=12	61.2	66.8	5.6	(-1.5, 12.7)	(-2.4, 13.5)	(-3.4, 14.6)	(-4.9, 16.0)	(-7.1, 18.3)	
Cortisol (mcg/24h): Day 35	55.0 (47.0, 120.0), n=13	62.0 (52.0, 73.0), n=13	61.6	66.9	5.3	(-19.1, 29.6)	(-21.9, 32.5)	(-25.5, 36.1)	(-30.2, 40.7)	(-37.6, 48.2)	
Urinary [THF+alloTHF]/THE ratio: Day 35	0.89 (0.88, 1.24), n=13	0.10 (0.08, 0.12), n=13	1.00	0.13	-0.87	(-0.98, -0.75)	(-1.00, -0.73)	(-1.01, -0.72)	(-1.04, -0.69)	(-1.07, -0.66)	
Biopsy AZD4017: Day 28	<5 (<5, <5), n=13	1570 ( 876, 2440), n=14									
Plasma AZD4017: Day 35	<5 (<5, <5), n=7	6490 (2960, 9040), n=12									
Variable	Observed mean (SD)		Estimated mean*		Difference*		Confidence interval*				
	PCB	AZD	PCB N=14	AZD N=14	AZD-PCB	75%	80%	85%	90%	95%	
Wound gap diameter (mm): Day 2	1.49 (0.72), n=14	0.98 (0.70), n=14	1.51	0.98	-0.52	(-0.82, -0.23)	(-0.85, -0.20)	(-0.89, -0.15)	(-0.95, -0.10)	(-1.04, -0.01)	
Wound depth (mm): Day 7	0.60 (0.23), n=14	0.59 (0.16), n=14	0.60	0.59	-0.01	(-0.10, 0.09)	(-0.11, 0.10)	(-0.13, 0.11)	(-0.15, 0.13)	(-0.17, 0.16)	
Wound gap diameter (mm): Day 30	1.44 (0.70), n=11	0.65 (0.49), n=12	1.35	0.70	-0.65	(-0.99, -0.32)	(-1.03, -0.28)	(-1.08, -0.23)	(-1.15, -0.16)	(-1.25, -0.05)	
Wound depth (mm): Day 35	0.60 (0.17), n=13	0.54 (0.21), n=12	0.59	0.56	-0.03	(-0.12, 0.05)	(-0.13, 0.06)	(-0.14, 0.07)	(-0.16, 0.09)	(-0.18, 0.12)	
Variable	Observed log scale mean (SD); geometric mean		Estimated geometric mean*		Ratio*		Confidence interval*				
	PCB N=14	AZD N=14	PCB N=14	AZD N=14	AZD:PCB	75%	80%	85%	90%	95%	
Hour 3 TEWL (Set 1; Day 0)	3.6 ( 0.3); 34.9, n=14	3.4 ( 0.2); 30.8, n=12	35.1	32.0	0.91	(0.81, 1.03)	(0.79, 1.05)	(0.78, 1.07)	(0.76, 1.09)	(0.73, 1.13)	
Hour 48 TEWL (Set 1; Day 2)	3.0 ( 0.3); 19.8, n=14	3.1 ( 0.4); 21.3, n=11	20.4	20.6	1.01	(0.86, 1.19)	(0.84, 1.21)	(0.82, 1.24)	(0.79, 1.28)	(0.76, 1.34)	
Hour 168 TEWL (Set 1; Day 7)	2.6 ( 0.3); 13.5, n=13	2.8 ( 0.7); 16.1, n=13	14.1	15.6	1.11	(0.86, 1.44)	(0.83, 1.49)	(0.80, 1.54)	(0.76, 1.62)	(0.70, 1.76)	
Hour 3 TEWL (Set 2; Day 28)	3.2 ( 0.5); 23.8, n=13	3.4 ( 0.3); 29.8, n=14	23.0	30.7	1.33	(1.09, 1.63)	(1.06, 1.67)	(1.03, 1.72)	(0.99, 1.79)	(0.93, 1.90)	
Hour 48 TEWL (Set 2; Day 30)	2.7 ( 0.4); 14.4, n=13	2.9 ( 0.4); 18.2, n=14	14.6	18.4	1.26	(1.03, 1.53)	(1.01, 1.56)	(0.98, 1.61)	(0.94, 1.67)	(0.89, 1.77)	
Hour 168 TEWL (Set 2; Day 35)	2.3 ( 0.4); 10.0, n=13	2.4 ( 0.4); 10.8, n=12	10.1	10.8	1.07	(0.87, 1.31)	(0.85, 1.34)	(0.82, 1.38)	(0.79, 1.44)	(0.74, 1.53)	
Hour 0 TEWL (Set 3; Day 35)	1.9 ( 0.4); 7.0, n=13	2.2 ( 0.5); 8.9, n=12	6.9	9.2	1.33	(1.07, 1.65)	(1.04, 1.69)	(1.01, 1.75)	(0.97, 1.82)	(0.91, 1.95)	
N tapes required for barrier disruption: Day 28	3.6 ( 0.6); 37.9, n=13	4.0 ( 0.4); 55.6, n=14	39.0	55.8	1.43	(1.18, 1.74)	(1.15, 1.78)	(1.12, 1.84)	(1.07, 1.91)	(1.01, 2.02)	

\*Estimated via multiple imputation, adjusted for baseline value (if applicable), age, sex and baseline HbA1c.

**Table 3: Longitudinal laboratory safety variables; adjusted differences between treatment groups**

Population: Safety set. All point estimates and confidence intervals estimated via linear regression.

Variable	Mean* PCB (N=14), AZD (N=14); Difference* AZD-PCB (90% CI)			
	Day 7	Day 28	Day 35	Day 42
Body Mass Index (kg / m2)	N/A	N/A	34.53, 34.94; 0.41 (-0.51, 1.34)	N/A
Waist-hip ratio	N/A	N/A	0.99, 1.01; 0.02 (-0.01, 0.05)	N/A
Systolic blood pressure (mm Hg)	N/A	N/A	143.68, 128.94; -14.74 (-23.00, -6.47)	138.44, 139.20; 0.77 (-6.58, 8.11)
Diastolic blood pressure (mm Hg)	N/A	N/A	78.00, 75.56; -2.43 (-7.67, 2.80)	78.56, 80.65; 2.09 (-6.77, 10.95)
HbA1c (mmol/mol)	68.77, 68.95; 0.18 (-1.51, 1.88)	67.05, 69.22; 2.17 (-0.64, 4.99)	67.43, 68.16; 0.72 (-3.64, 5.09)	66.28, 68.69; 2.42 (-2.38, 7.22)
High density lipoprotein (mmol/l)	1.13, 1.07; -0.06 (-0.14, 0.02)	1.13, 1.06; -0.08 (-0.16, 0.00)	1.09, 0.96; -0.13 (-0.21, -0.05)	1.06, 1.11; 0.05 (-0.07, 0.16)
Cholesterol (mmol/l)	4.15, 3.74; -0.42 (-0.60, -0.23)	4.10, 3.64; -0.46 (-0.79, -0.12)	4.00, 3.49; -0.51 (-0.87, -0.15)	3.91, 3.81; -0.10 (-0.54, 0.34)
Triglycerides (mmol/l)	2.32, 2.18; -0.14 (-0.67, 0.40)	2.12, 1.93; -0.19 (-0.56, 0.18)	2.96, 2.48; -0.48 (-1.21, 0.24)	2.79, 2.81; 0.02 (-0.51, 0.55)
Haemoglobin (g/l)	136.42, 137.08; 0.67 (-2.12, 3.45)	136.91, 135.94; -0.98 (-4.13, 2.17)	133.37, 134.00; 0.64 (-3.96, 5.24)	131.15, 133.22; 2.07 (-1.62, 5.76)
White cells (x10 <sup>9</sup> /l)	7.06, 7.60; 0.54 (-0.14, 1.22)	6.93, 6.54; -0.40 (-0.87, 0.08)	6.97, 6.67; -0.31 (-0.96, 0.34)	6.98, 7.31; 0.33 (-0.41, 1.07)
Platelets (x10 <sup>9</sup> /l)	246.02, 248.45; 2.42 (-13.65, 18.50)	247.32, 260.65; 13.32 (-9.56, 36.20)	241.23, 240.32; -0.91 (-25.20, 23.37)	245.18, 246.65; 1.47 (-16.74, 19.68)
Red cells (x10 <sup>12</sup> /l)	4.69, 4.64; -0.05 (-0.17, 0.06)	4.70, 4.65; -0.05 (-0.15, 0.04)	4.56, 4.55; -0.02 (-0.15, 0.12)	4.45, 4.60; 0.15 (0.03, 0.26)
Mean corpuscular volume (fl)	90.88, 90.99; 0.11 (-1.83, 2.05)	90.48, 91.00; 0.52 (-1.49, 2.53)	91.91, 91.74; -0.17 (-2.53, 2.19)	91.01, 91.17; 0.16 (-1.42, 1.73)
Haematocrit (packed cell volume)	0.43, 0.42; -0.01 (-0.02, 0.01)	0.42, 0.43; 0.00 (-0.01, 0.02)	0.41, 0.41; 0.00 (-0.02, 0.02)	0.40, 0.41; 0.02 (0.00, 0.03)
Mean corpuscular haemoglobin (pg)	29.26, 29.67; 0.41 (0.08, 0.75)	29.34, 29.27; -0.07 (-0.44, 0.31)	29.46, 29.63; 0.17 (-0.28, 0.62)	29.60, 29.17; -0.42 (-0.95, 0.10)
Corpuscular haemoglobin concentration (g/l)	321.59, 326.49; 4.91 (-1.41, 11.22)	326.54, 322.74; -3.80 (-10.80, 3.21)	322.83, 324.58; 1.75 (-4.85, 8.35)	327.15, 321.93; -5.22 (-12.18, 1.74)
Red blood cell distribution width (%)	14.52, 14.17; -0.36 (-0.89, 0.18)	14.36, 14.27; -0.09 (-0.49, 0.31)	14.52, 14.63; 0.11 (-0.28, 0.51)	14.23, 14.03; -0.21 (-0.68, 0.26)
Albumin (g/l)	39.64, 40.01; 0.37 (-0.82, 1.55)	39.14, 38.77; -0.37 (-1.82, 1.09)	39.73, 39.73; -0.01 (-1.60, 1.59)	38.52, 38.91; 0.40 (-0.59, 1.38)
Bilirubin (umol/l)	8.03, 8.96; 0.93 (-1.14, 3.00)	9.06, 9.67; 0.60 (-0.89, 2.09)	9.14, 8.50; -0.64 (-3.01, 1.73)	8.44, 8.79; 0.35 (-1.17, 1.87)
Alkaline phosphatase (U/l)	83.41, 77.41; -6.00 (-12.44, 0.44)	80.09, 67.71; -12.39 (-20.21, -4.56)	77.45, 64.36; -13.09 (-20.43, -5.75)	75.90, 70.24; -5.65 (-15.25, 3.95)
Alanine aminotransferase (iu/l)	23.94, 25.10; 1.16 (-1.84, 4.15)	22.46, 20.50; -1.96 (-4.94, 1.03)	21.13, 19.49; -1.64 (-5.88, 2.61)	18.78, 19.56; 0.78 (-3.00, 4.56)
Aspartate aminotransferase (iu/l)	21.49, 21.95; 0.46 (-2.29, 3.21)	20.81, 20.93; 0.12 (-1.81, 2.05)	20.63, 20.59; -0.04 (-2.52, 2.45)	18.88, 21.09; 2.21 (-1.02, 5.44)
Gamma-glutamyl transpeptidase (iu/l)	38.34, 39.10; 0.76 (-2.83, 4.35)	39.34, 29.06; -10.28 (-14.96, -5.60)	40.60, 28.62; -11.97 (-22.80, -1.15)	39.57, 30.03; -9.55 (-14.88, -4.22)
eGFR (ml/min/1.73m <sup>2</sup> )	76.12, 72.94; -3.18 (-8.30, 1.94)	74.78, 72.59; -2.19 (-5.38, 1.01)	68.65, 68.92; 0.27 (-4.57, 5.10)	65.69, 67.31; 1.62 (-2.77, 6.01)
Sodium (mmol/l)	139.60, 139.70; 0.10 (-1.23, 1.44)	138.37, 138.52; 0.16 (-0.98, 1.29)	140.03, 138.84; -1.19 (-3.21, 0.82)	139.07, 137.82; -1.25 (-2.42, -0.07)
Potassium (mmol/l)	4.85, 4.54; -0.31 (-0.58, -0.03)	4.68, 4.86; 0.18 (-0.06, 0.43)	4.53, 4.54; 0.01 (-0.22, 0.25)	4.65, 4.61; -0.04 (-0.31, 0.22)
Urea (mmol/l)	7.02, 7.15; 0.13 (-0.79, 1.05)	6.72, 6.37; -0.35 (-1.31, 0.61)	7.34, 6.82; -0.52 (-1.88, 0.83)	7.51, 7.53; 0.02 (-1.04, 1.08)
Creatinine (umol/l)	81.73, 89.16; 7.43 (0.79, 14.08)	83.09, 86.52; 3.43 (-0.98, 7.85)	91.89, 93.67; 1.78 (-5.65, 9.22)	95.86, 94.28; -1.58 (-8.24, 5.07)
Testosterone (nmol/l)	8.70, 8.06; -0.63 (-2.52, 1.25)	8.98, 7.92; -1.06 (-2.58, 0.45)	8.51, 8.10; -0.40 (-2.66, 1.85)	7.96, 9.08; 1.12 (-1.20, 3.45)
Dehydroepiandrosterone sulphate (umol/l)	3.09, 5.39; 2.30 (1.52, 3.08)	2.74, 5.60; 2.86 (2.09, 3.64)	2.65, 4.82; 2.16 (1.29, 3.04)	2.30, 3.39; 1.09 (0.43, 1.75)
Free thyroxine (pmol/l)	14.94, 15.44; 0.50 (-0.63, 1.64)	14.71, 15.21; 0.51 (-0.43, 1.44)	14.32, 14.97; 0.65 (-0.45, 1.76)	13.61, 14.41; 0.79 (0.07, 1.52)
Thyroid stimulating hormone (mIU/l)	1.71, 1.81; 0.10 (-0.22, 0.42)	1.87, 1.68; -0.20 (-0.58, 0.19)	1.89, 1.74; -0.15 (-0.54, 0.23)	1.95, 1.91; -0.04 (-0.46, 0.38)

\*Estimated in imputed data, adjusted for baseline value, age, sex and baseline HbA1c.

**Table 4: Adverse event summary**

Population: Safety set

<b>Adverse events (AE)</b>	<b>PCB (n=14)</b>	<b>AZD (n=14)</b>	<b>All patients (n=28)</b>
Total AE: n (n per PY)	13 (8.3)	24 (13.8)	37 (11.1)
Unique AE: n (n per PY)	13 (8.3)	16 (9.2)	29 (8.7)
Patients with >=1 AE: n (%)	8 (57)	10 (71)	18 (64)
Discontinuation due to AE: n (%)	0 (-)	0 (-)	0 (-)
<b>AE by SOC: n total (n unique*), n patients (%)</b>			
Blood	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Cardiac	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Congenital	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Ear	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Endocrine	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Eye	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Gastrointestinal	9 (9), 6 (43)	14 (8), 7 (50)	23 (17), 13 (46)
General	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Hepatobiliary	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Immune	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Infections	0 (0), 0 (-)	1 (1), 1 (7)	1 (1), 1 (4)
Injury	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Investigations	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Metabolism	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Musculoskeletal	0 (0), 0 (-)	1 (1), 1 (7)	1 (1), 1 (4)
Neoplasms	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Nervous system	1 (1), 1 (7)	6 (4), 4 (29)	7 (5), 5 (18)
Pregnancy	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Psychiatric	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Renal	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Reproductive system	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Respiratory	2 (2), 1 (7)	2 (2), 1 (7)	4 (4), 2 (7)
Skin	1 (1), 1 (7)	0 (0), 0 (-)	1 (1), 1 (4)
Social	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Surgical	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
Vascular	0 (0), 0 (-)	0 (0), 0 (-)	0 (0), 0 (-)
<b>AE severity: n*</b>			
Mild	13	13	26
Moderate	0	3	3
Severe	0	0	0
Life-threatening	0	0	0
Death	0	0	0
<b>AE by relation to study drug: n*</b>			
Not related	0	1	1
Unlikely	4	4	8
Possible	9	11	20
Probable	0	0	0
Definite	0	0	0
<b>SAE</b>			
Total SAE: n	0	1	1
Patients with >=1 SAE: n (%)	0 (-)	1 (7)	1 (4)

\* Recurrent AEs counted once at maximum severity/relatedness reported. SOC=CTCAE system order class; PY=patient year